Mindbio Therapeutics CEO Issues Letter To Shareholders
Mindbio Therapeutics CEO Issues Letter To Shareholders
Mindbio治疗公司CEO向股东发出信函
Dear Shareholders,
亲爱的股东：
We are delighted to provide an update on progress at MindBio, as we head into the second half of 2024 and continue with dosing in multiple Phase 2B clinical trials and we advance the Company closer towards its commercialisation objective.
我们很高兴地向您提供MindBio在2024年下半年的进展情况，同时在多个20亿期的临床试验中进行给药，让公司更接近商业化目标。
The Company is pleased to report on its two currently dosing Phase 2B clinical trials which include assessing MB22001, MindBio's lead candidate drug in treating the following conditions:
公司很高兴地报告其两个目前进行第20亿期临床试验的情况，这两个试验包括评估MindBio的主要候选药物MB22001治疗以下疾病的情况：
MindBio Leads Global Public Companies in Non-hallucinogenic Psychedelic Clinical Trials
MindBio在非幻觉热带灵与临床试验中的领先全球公开公司
MindBio is the only publicly listed company in the world specializing in a scalable psychedelic microdosing treatment model that is sub-hallucinogenic...
MindBio是全球唯一专注于可扩展的微量剂...
登录免费看全文
登录/注册